Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation - ANTIPAF

Description:

The goal of the trial was to evaluate treatment with olmesartan compared with placebo among patients with paroxysmal atrial fibrillation (AF) without structural heart disease.